Special Drug Use Surveillance of Irribow in Female Patients
NCT ID: NCT02612649
Last Updated: 2024-10-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
793 participants
OBSERVATIONAL
2015-10-01
2018-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Evaluate Efficacy of Ramosetron on Diarrhea-predominant Irritable Bowel Syndrome (IBS) in Male Patients
NCT01225237
A Preliminary Study to Explore Clinical Endpoints in Patients (Male) With Diarrhea-predominant Irritable Bowel Syndrome
NCT00918411
A Study to Evaluate Efficacy of YM060 on Diarrhea-predominant Irritable Bowel Syndrome (D-IBS) in Female Patients
NCT01274000
A Long Term Study of YM060 in Female Patients With Diarrhea-predominant Irritable Bowel Syndrome
NCT01736423
A Study to Assess the Efficacy and Safety of YM060 in Female Patients With Diarrhea-predominant Irritable Bowel Syndrome (IBS)
NCT01870895
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Ramosetron group
Female patients with diarrhea-predominant irritable bowel syndrome
Ramosetron
Oral
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ramosetron
Oral
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Astellas Pharma Inc
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Director
Role: STUDY_DIRECTOR
Astellas Pharma Inc
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Numakunai, Iwate, Japan
Aichi, , Japan
Akita, , Japan
Chiba, , Japan
Fukui, , Japan
Fukuoka, , Japan
Fukushima, , Japan
Gifu, , Japan
Gunma, , Japan
Hiroshima, , Japan
Hyōgo, , Japan
Ibaraki, , Japan
Kagoshima, , Japan
Kanagawa, , Japan
Kumamoto, , Japan
Kyoto, , Japan
Mie, , Japan
Miyagi, , Japan
Miyazaki, , Japan
Nagano, , Japan
Niigata, , Japan
Okayama, , Japan
Okinawa, , Japan
Osaka, , Japan
Ōita, , Japan
Saitama, , Japan
Shiga, , Japan
Shizuoka, , Japan
Tochigi, , Japan
Tokyo, , Japan
Tottori, , Japan
Toyama, , Japan
Yamagata, , Japan
Yamaguchi, , Japan
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IB0002
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.